Seaport Therapeutics raised $255M in an upsized IPO in the United States, selling 14.16M shares at $18 each. The offering exceeded the initial target of $212.4M. Previously, Boston-based Seaport had planned to raise up to $212.4 million by offering 11.8 million shares priced between $16 and $18 each. The clinical-stage biotech firm is developing oral therapies for neuropsychiatric disorders.

Reviving Biotech Capital Flows